ATE496064T1 - Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten - Google Patents

Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten

Info

Publication number
ATE496064T1
ATE496064T1 AT03722301T AT03722301T ATE496064T1 AT E496064 T1 ATE496064 T1 AT E496064T1 AT 03722301 T AT03722301 T AT 03722301T AT 03722301 T AT03722301 T AT 03722301T AT E496064 T1 ATE496064 T1 AT E496064T1
Authority
AT
Austria
Prior art keywords
insulin
formulations containing
containing monomeric
acylated
soluble formulations
Prior art date
Application number
AT03722301T
Other languages
English (en)
Inventor
Liselotte Langkjaer
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of ATE496064T1 publication Critical patent/ATE496064T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AT03722301T 2002-05-07 2003-05-02 Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten ATE496064T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200200683 2002-05-07
PCT/DK2003/000288 WO2003094956A1 (en) 2002-05-07 2003-05-02 Soluble formulations comprising monomeric insulin and acylated insulin

Publications (1)

Publication Number Publication Date
ATE496064T1 true ATE496064T1 (de) 2011-02-15

Family

ID=29414624

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03722301T ATE496064T1 (de) 2002-05-07 2003-05-02 Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten

Country Status (8)

Country Link
US (2) US20040006000A1 (de)
EP (1) EP1506230B1 (de)
JP (2) JP5599543B2 (de)
AT (1) ATE496064T1 (de)
AU (1) AU2003236201A1 (de)
DE (1) DE60335797D1 (de)
ES (1) ES2360182T3 (de)
WO (1) WO2003094956A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2360182T3 (es) * 2002-05-07 2011-06-01 Novo Nordisk A/S Formulaciones solubles que comprenden insulina monomérica e insulina acilada.
JP4463814B2 (ja) * 2003-08-05 2010-05-19 ノボ ノルディスク アクティーゼルスカブ 新規のインスリン誘導体
JP5248113B2 (ja) * 2004-11-12 2013-07-31 ノヴォ ノルディスク アー／エス ペプチドの安定な処方
ATE519780T1 (de) 2005-12-28 2011-08-15 Novo Nordisk As Ein acyliertes insulin und zink enthaltende zusammensetzungen und verfahren zur herstellung dieser zusammensetzungen
FR2896247B1 (fr) 2006-01-13 2008-02-29 Sanofi Aventis Sa Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
BRPI0717098B8 (pt) 2006-09-22 2021-05-25 Novo Nordisk As análogos de insulina humana resistentes à protease, composição farmacêutica e processo para sua preparação
US9387176B2 (en) 2007-04-30 2016-07-12 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
ES2744384T3 (es) 2007-06-13 2020-02-24 Novo Nordisk As Formulación farmacéutica que comprende un derivado de insulina
JP5241849B2 (ja) 2007-11-16 2013-07-17 ノボ・ノルデイスク・エー／エス インスリン及びインスリン分泌性ペプチドを含む薬学的組成物
WO2009112583A2 (en) 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
MX2010009850A (es) 2008-03-18 2010-09-30 Novo Nordisk As Analogos de insulina acilados y etabilizados contra proteasas.
RU2458989C1 (ru) * 2008-08-07 2012-08-20 Байокон Лимитид Способ получения аналогов инсулина из их соответствующих предшественников (варианты)
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
JP4959005B2 (ja) 2008-10-30 2012-06-20 ノボ・ノルデイスク・エー／エス 毎日の注射頻度より少ないインスリン注射での真性糖尿病の治療
KR101635689B1 (ko) 2009-01-28 2016-07-01 스마트쎌스, 인크. 제어 약물 전달을 위한 접합체 기재 시스템
US8940690B2 (en) 2009-01-28 2015-01-27 National Institutes Of Health (Nih) Synthetic conjugates and uses thereof
HUE026102T2 (en) * 2009-02-04 2016-05-30 Sanofi Aventis Deutschland Medical device and procedure for glycemic control
JP2012520879A (ja) 2009-03-20 2012-09-10 スマートセルズ・インコーポレイテツド 末端官能基化コンジュゲートおよびその用途
MY180661A (en) 2009-11-13 2020-12-04 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
AU2010317994B2 (en) 2009-11-13 2014-03-06 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist and methionine
CN101912600B (zh) * 2010-01-11 2014-01-29 杨国汉 改善胰岛素在溶液中稳定性的方法
US9180261B2 (en) * 2010-01-12 2015-11-10 Dance Biopharm Inc. Preservative free insulin formulations and systems and methods for aerosolizing
US10842951B2 (en) 2010-01-12 2020-11-24 Aerami Therapeutics, Inc. Liquid insulin formulations and methods relating thereto
US20140148384A1 (en) 2010-08-30 2014-05-29 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
BR112013010345A2 (pt) 2010-10-27 2017-07-25 Novo Nordisk As tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção
WO2012055840A1 (en) * 2010-10-28 2012-05-03 Bayer Pharma Aktiengesellschaft Composition and preparation for treatment of dysmenorrhea and menstrual pain and use of a hormonal agent and a zinc salt for treatment of menstrual disorders
RU2013130374A (ru) * 2010-12-14 2015-01-20 Ново Нордиск А/С Препарат, содержащий инсулин, никотинамид и аминокислоту
EP2651432A1 (de) 2010-12-14 2013-10-23 Novo Nordisk A/S Schnellwirkendes insulin in verbindung mit langwirkendem insulin
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
BR112014004726A2 (pt) 2011-08-29 2017-04-04 Sanofi Aventis Deutschland combinação farmacêutica para uso no controle glicêmico em pacientes de diabetes tipo 2
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
CN104364260B (zh) 2012-04-11 2017-02-22 诺和诺德股份有限公司 胰岛素制剂
KR102205512B1 (ko) 2012-11-13 2021-01-20 아도시아 치환된 음이온성 화합물을 포함하는 속효성 인슐린 제형
CA2890048C (en) 2012-12-03 2022-05-03 Merck Sharp & Dohme Corp. O-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues
TWI641381B (zh) * 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
EP2991672A1 (de) 2013-04-30 2016-03-09 Novo Nordisk A/S Neuartiges verabreichungsschema
US9896496B2 (en) 2013-10-07 2018-02-20 Novo Nordisk A/S Derivative of an insulin analogue
SG11201604706TA (en) 2014-01-09 2016-07-28 Sanofi Sa Stabilized pharmaceutical formulations of insulin aspart
JP7173953B2 (ja) * 2014-01-09 2022-11-16 サノフイ インスリンアナログおよび／またはインスリン誘導体の安定化された医薬製剤
AU2015205621A1 (en) 2014-01-09 2016-07-14 Sanofi Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
JP6641280B2 (ja) 2014-01-09 2020-02-05 サノフイＳａｎｏｆｉ インスリンアナログおよび／またはインスリン誘導体の安定化された医薬製剤
JO3624B1 (ar) * 2014-05-08 2020-08-27 Lilly Co Eli تركيبات إنسولين سريعة المفعول
EP3229828B1 (de) 2014-12-12 2023-04-05 Sanofi-Aventis Deutschland GmbH Insulin-glargin/lixisenatid-fixierte verhältnisformulierung
WO2016137569A1 (en) 2015-02-25 2016-09-01 Dance Biopharm, Inc. Liquid insulin formulations and methods relating thereto
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
JO3749B1 (ar) 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
WO2018109162A1 (en) 2016-12-16 2018-06-21 Novo Nordisk A/S Insulin containing pharmaceutical compositions
GB201707187D0 (en) * 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
EP3727424A4 (de) 2017-12-18 2021-10-27 Merck Sharp & Dohme Corp. Konjugatbasierte systeme für kontrollierte insulinfreisetzung
US11413352B2 (en) 2017-12-18 2022-08-16 Merck, Sharp & Dohme LLC Conjugate based systems for controlled insulin delivery
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
CR20220555A (es) 2020-03-31 2023-01-23 Protomer Tech Inc Conjugados para reactividad selectiva a dioles vecinales
EP4247429A1 (de) 2020-11-19 2023-09-27 Protomer Technologies Inc. Aromatische borhaltige verbindungen und insulinanaloga
TW202409070A (zh) 2022-05-18 2024-03-01 美商普羅托莫科技公司 芳族含硼化合物及相關胰島素類似物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU550068B2 (en) 1981-03-10 1986-02-27 Novo Nordisk A/S Zinc insulin stabilized with calcium or magnesium salts
NL193099C (nl) 1981-10-30 1998-11-03 Novo Industri As Gestabiliseerde insuline-oplossing.
FI78616C (fi) 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
US4839341A (en) * 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
SI0792290T1 (en) * 1993-09-17 2001-12-31 Novo Nordisk As Acylated insulin
US5547929A (en) 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
DE69629210T2 (de) 1995-03-17 2004-04-22 Novo Nordisk A/S Insulinabkömmlinge
US20010041786A1 (en) 1995-06-07 2001-11-15 Mark L. Brader Stabilized acylated insulin formulations
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
ZA984697B (en) * 1997-06-13 1999-12-01 Lilly Co Eli Stable insulin formulations.
DE19726167B4 (de) * 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
US6531448B1 (en) 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
HUP0104111A3 (en) * 1998-10-16 2002-05-28 Novo Nordisk As Stable concentrated insulin preparations for pulmonary delivery
ATE220917T1 (de) * 1999-01-26 2002-08-15 Lilly Co Eli Monodisperse formulierungen, die hexamere acylierte insulinanaloge enthalten
US6589229B1 (en) * 2000-07-31 2003-07-08 Becton, Dickinson And Company Wearable, self-contained drug infusion device
AU2003208316A1 (en) * 2002-03-13 2003-09-22 Novo Nordisk A/S Minimising body weight gain in insulin treatment
ES2360182T3 (es) * 2002-05-07 2011-06-01 Novo Nordisk A/S Formulaciones solubles que comprenden insulina monomérica e insulina acilada.

Also Published As

Publication number Publication date
JP2006511441A (ja) 2006-04-06
JP2012233003A (ja) 2012-11-29
US20050261168A1 (en) 2005-11-24
AU2003236201A1 (en) 2003-11-11
US20040006000A1 (en) 2004-01-08
ES2360182T3 (es) 2011-06-01
EP1506230A1 (de) 2005-02-16
JP5599543B2 (ja) 2014-10-01
EP1506230B1 (de) 2011-01-19
US7387996B2 (en) 2008-06-17
WO2003094956A1 (en) 2003-11-20
DE60335797D1 (de) 2011-03-03

Similar Documents

Publication Publication Date Title
ATE496064T1 (de) Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten
HRP20080564T3 (en) Dihydrotetrabenazines and pharmaceutical compositions containing them
HRP20070374T3 (en) Formulations comprising ecteinascidin and a disaccharide
MXPA03011935A (es) Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco.
TW200505875A (en) Novel compounds
TW200601970A (en) Insecticidal benzenedicarboxamides
UA84271C2 (en) Formate salt of o-desmethyl-venlafaxine
EA200701172A1 (ru) 2-алкокси-3,4,5-тригидроксиалкиламиды, их получение, композиции, их содержащие, и применение
ATE431749T1 (de) Topische zusammensetzung enthaltend ein cyclofructan, einen träger und einen arzneistoff
MXPA06002349A (es) Derivados de aminopropanol.
EP1731609A4 (de) Rad51-expressionsinhibitor, den inhibitor als wirkstoff enthaltender arzneistoff und nutzung davon
RS51575B (en) ESCITALOPRAM CRYSTAL DATABASE AND ORODISPERSIBLE TABLES CONTAINING ESCITALOPRAM DATABASE
MXPA05011212A (es) Derivados de indeno como agentes farmaceuticos.
HRP20070291T3 (en) Pharmaceutical composition comprising a zinc-hyaluronate complex for the treatment of multiple sclerosis
MY134026A (en) ?-carboline derivatives and its pharmaceutical use against depression and anxiety
GEP20074075B (en) Indazolamides with analgesic activity
SV2006002238A (es) Inhibidores de la adenilato ciclasa soluble ref. p-sv-78. 959/gh
ITBO20020544A1 (it) Uso di farine vegetali come agenti biotossici ad azione ammendante.
TW200519103A (en) Pesticidal agents
DE60309480D1 (de) Vitamin d-analoge
DE60231385D1 (de) Formulierungen, die eingeschlossene wirkstoffe enthalten, und ihre verwendung
ITRM20010325A1 (it) Composizioni farmaceutiche a base di zeoliti contenenti zinco ed eritromicina da impiegare nella terapia anti-acne.
GEP20115184B (en) Pharmacokinetically improved compounds
TW200621304A (en) Pharmaceutical composition
TW200621224A (en) Pharmaceutical composition

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties